Gastroesophageal Cancers: Progress and Problems

Author:
Jaffer A. Ajani
Search for other papers by Jaffer A. Ajani in
Current site
Google Scholar
PubMedClose
 MD
Volume/Issue:
Volume 6: Issue 9
Online Publication Date:
Oct 2008
DOI:
https://doi.org/10.6004/jnccn.2008.0061
Full access

Jaffer A. Ajani, MD, an internationally recognized expert on gastrointestinal cancers, is Professor of Gastrointestinal Medical Oncology at M. D. Anderson Cancer Center and the Chair of the NCCN Clinical Practice Guidelines in Oncology Gastroesophageal Cancers Panel. He has participated over the past 20 years in numerous trials using innovative combined modality therapies for localized gastric and esophageal cancers, and some of his work led to the development of strategies of pre-operative therapy for resectable upper gastrointestinal cancers.

His current research focus is on developing programs to research the molecular markers for progression of Barrett's metaplasia to adenocarcinoma. These research efforts involve multi-institutional collaboration with investigators at the University of Chicago, University of Pennsylvania, Mayo Clinic, and Yonsei University, in Seoul, Korea.

In addition to his work with NCCN, Dr. Ajani participates actively in the International Society of Gastrointestinal Oncology is the editor of the Society's journal, Gastrointestinal Oncology Research.

  • Collapse
  • Expand
  • 1.

    Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.

  • 2.

    Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142–146.

    • Search Google Scholar
    • Export Citation
  • 3.

    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.

  • 4.

    Macdonald JS, Smalley SR, Benedetti J et al.. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.

    • Search Google Scholar
    • Export Citation
  • 5.

    Cooper JS, Guo MD, Herskovic A et al.. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623–1627.

    • Search Google Scholar
    • Export Citation
  • 6.

    Cunningham D, Allum WH, Stenning SP et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

    • Search Google Scholar
    • Export Citation
  • 7.

    DeMeester SR. New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy. Ann Thorac Surg 2008;85:S747–S750.

    • Search Google Scholar
    • Export Citation
  • 8.

    DeMeester SR. EMR for intramucosal adenocarcinoma of the esophagus: does one size fit all? Gastrointest Endosc 2007;65:14–15.

  • 9.

    DeMeester SR. Endoscopic mucosal resection and vagal-sparing esophagectomy for high-grade dysplasia and adenocarcinoma of the esophagus. Semin Thorac Cardiovasc Surg 2005;17:320–325.

    • Search Google Scholar
    • Export Citation
  • 10.

    Tanaka M, Ono H, Hasuike N, Takizawa K. Endoscopic submucosal dissection of early gastric cancer. Digestion 2008;77(Suppl 1):23–28.

  • 11.

    Kelsey CR, Chino JP, Willett CG et al.. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys 2007;69:770–776.

    • Search Google Scholar
    • Export Citation
  • 12.

    Javeri H, Arora R, Correa AM et al.. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 2008; in press.

    • Search Google Scholar
    • Export Citation
  • 13.

    De Roock W, Piessevaux H, De Schutter J et al.. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508–515.

    • Search Google Scholar
    • Export Citation
  • 14.

    Lievre A, Bachet JB, Le Corre D et al.. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992–3995.

    • Search Google Scholar
    • Export Citation
  • 15.

    Lievre A, Bachet JB, Boige V et al.. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–379.

    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2008 by the National Comprehensive Cancer Network
Page Numbers:
2
Article Category:
Editorial
Print Publication Date:
01 Oct 2008
Online Publication Date:
Oct 2008
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 358 157 16
PDF Downloads 284 144 12
EPUB Downloads 0 0 0